PharmAbcine Inc. products

PharmAbcine’s fully human antibody library provides the diversity of antibody candidates for target antigens, ensuring highest success rates of developing therapeutic antibodies for various indications. Our unique and diverse antibody repertoires are constructed by recombination of V gene segments and DJ gene segments in human B-cell derived antibody heavy chains, generating more than 100 billion antibodies in combination with light chain sequences. Naturally derived human sequences from our proprietary HuPhage library further assures low immunogenicity and reduces the related toxicities at the clinical setting.

Olinvacimab is an anti-angiogenic antibody that neutralizes the VEGF/VEGFR2 pathway, thus inhibiting tumor growth and metastasis.

PMC-309 is an engineered monoclonal antibody that targets the negative immune checkpoint human VISTA (V-domain Ig suppressor of T cell activation). It indirectly promotes T cells` immune responses by inhibiting VISTA-expressing immunosuppressive cells such as MDSCs (Myeloid-Derived Suppressor Cells) which suppress T cell inactivation and proliferation.

PMC-403 is a monoclonal antibody that targets the human TIE2 that regulate the angiogenesis and vessel maturation in endothelial cells. It binds to TIE2 expressing endothelial cells and normalize VEGF-induced pathological leaky blood vessels in eyes and TME (tumor microenvironment).

PMC-402 is a monoclonal antibody that targets the human TIE2 that regulated activation, proliferation, and repolarization of Tie2 expressing macrophages, resulting in T cell activation. It binds to TIE2 expressing macrophages that activate T cells in the tumor microenvironment (TME).